ATE530635T1 - Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status - Google Patents

Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status

Info

Publication number
ATE530635T1
ATE530635T1 AT02753517T AT02753517T ATE530635T1 AT E530635 T1 ATE530635 T1 AT E530635T1 AT 02753517 T AT02753517 T AT 02753517T AT 02753517 T AT02753517 T AT 02753517T AT E530635 T1 ATE530635 T1 AT E530635T1
Authority
AT
Austria
Prior art keywords
amount
kit
biological
individual
scf
Prior art date
Application number
AT02753517T
Other languages
English (en)
Inventor
Sarah Bacus
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of ATE530635T1 publication Critical patent/ATE530635T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT02753517T 2001-08-21 2002-08-21 Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status ATE530635T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31418801P 2001-08-21 2001-08-21
PCT/US2002/026811 WO2003016867A2 (en) 2001-08-21 2002-08-21 Method and quantification assay for determining c-kit/scf/pakt status

Publications (1)

Publication Number Publication Date
ATE530635T1 true ATE530635T1 (de) 2011-11-15

Family

ID=23218931

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02753517T ATE530635T1 (de) 2001-08-21 2002-08-21 Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status

Country Status (8)

Country Link
US (2) US7419777B2 (de)
EP (2) EP1427810B9 (de)
JP (1) JP4204974B2 (de)
AT (1) ATE530635T1 (de)
AU (2) AU2007201809B2 (de)
CA (1) CA2457799C (de)
ES (1) ES2376422T3 (de)
WO (1) WO2003016867A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500041A (ja) * 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
EP1401412A2 (de) * 2001-06-29 2004-03-31 AB Science Verwendung von potenten, selektiven und nontoxischen c-kithemmer zur behandlung von tumorangiogenese
WO2003002106A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitions for treating allergic diseases
JP2004537537A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
US7563584B2 (en) * 2001-07-10 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US7695926B2 (en) * 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US20030219772A1 (en) * 2001-09-28 2003-11-27 Kuyl Antoinette Cornelia Van Der Means and methods for treatment evaluation
US6944333B2 (en) * 2003-04-30 2005-09-13 Ventana Medical Systems, Inc. Color image compression via spectral decorrelation and elimination of spatial redundancy
GB0315991D0 (en) * 2003-07-08 2003-08-13 Dakocytomation Denmark As Standard
US8068988B2 (en) 2003-09-08 2011-11-29 Ventana Medical Systems, Inc. Method for automated processing of digital images of tissue micro-arrays (TMA)
WO2005027015A2 (en) 2003-09-10 2005-03-24 Bioimagene, Inc. Method and system for quantitatively analyzing biological samples
US20070292887A1 (en) * 2003-11-04 2007-12-20 Bayer Pharmaceuticals Corporation Immunohistochemical Methods
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
CN101194260A (zh) * 2005-01-24 2008-06-04 利兰·斯坦福青年大学托管委员会 使用贝叶斯网络建立细胞信号传导系统模型的方法
EP1889032A1 (de) * 2005-05-25 2008-02-20 Stiftelsen Universitetsforskning Bergen Mikroskopsystem und screening-verfahren für arzneistoffe, physische therapien und biologische gefahrstoffe
US8609640B2 (en) 2007-07-25 2013-12-17 Eisai, Inc. Multikinase inhibitors for use in the treatment of cancer
US20090170925A1 (en) * 2007-10-29 2009-07-02 Eisai R&D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
JP5040597B2 (ja) 2007-11-06 2012-10-03 日本電気株式会社 評価システム、評価方法および評価プログラム
WO2009102729A1 (en) * 2008-02-11 2009-08-20 Historx, Inc. Association of biomarkers with patient outcome
WO2009134944A2 (en) * 2008-04-29 2009-11-05 Nodality, Inc. Methods of determining the health status of an individual
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2010006291A1 (en) * 2008-07-10 2010-01-14 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US8557527B2 (en) * 2008-09-22 2013-10-15 Historx, Inc. Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib
EP2667194A3 (de) 2009-01-14 2014-06-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Auf Verhältnis basierende Biomarker und Verfahren zu ihrer Verwendung
WO2010141459A1 (en) * 2009-06-01 2010-12-09 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of pten
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
WO2017051327A1 (en) * 2015-09-22 2017-03-30 Imageprovision Technology Pvt. Ltd. Method and system for detection and classification of particles based on processing of microphotographic images
EP3440580A4 (de) * 2016-04-05 2019-12-04 The Board of Trustees of the Leland Stanford Junior University Systeme und verfahren für gezielte therapie auf der basis der reaktion auf einzelzellenstimulusstörung
JP7642531B2 (ja) 2018-05-11 2025-03-10 ビーム セラピューティクス インク． プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法
GB201815123D0 (en) * 2018-09-17 2018-10-31 Micromass Ltd Tissue analysis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288477A (en) * 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
US5536642A (en) * 1993-09-09 1996-07-16 Barbera-Guillem; Emilio Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
US5663315A (en) * 1994-12-06 1997-09-02 Alphagene, Inc. Isolated DNA encoding human GP2
EP0816848A1 (de) 1996-06-28 1998-01-07 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zum vergleichenden Screenen von Substanzen mit pharmakologischer Wirkung
BR9907852A (pt) 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
CA2324995A1 (en) 1998-04-17 1999-10-28 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
KR20020079364A (ko) * 1999-06-28 2002-10-19 소스 프리시전 메디슨, 인코포레이티드 보정된 유전자 발현 프로파일을 이용한 생물학적 상태또는 물질을 특성화하기 위한 시스템 및 방법
ES2267605T3 (es) * 1999-12-22 2007-03-16 Sugen, Inc. Uso de compuestos de indolinona para la fabricacion de productos farmaceuticos destinados a modular la funcion de la c-kit-tirosina-proteina-quinasa.
AU2951801A (en) * 2000-01-12 2001-07-24 Ventana Medical Systems, Inc. Method for quantitating a protein by image analysis
US6406669B1 (en) 2001-01-12 2002-06-18 The Regents Of The University Of California Polyaniline-based optical ammonia detector

Also Published As

Publication number Publication date
US7419777B2 (en) 2008-09-02
EP1427810B1 (de) 2011-10-26
US9625446B2 (en) 2017-04-18
CA2457799A1 (en) 2003-02-27
EP1427810A4 (de) 2005-02-02
EP2277991A1 (de) 2011-01-26
ES2376422T3 (es) 2012-03-13
AU2010241288A1 (en) 2010-11-25
US20030045451A1 (en) 2003-03-06
WO2003016867A3 (en) 2003-08-28
JP4204974B2 (ja) 2009-01-07
WO2003016867A2 (en) 2003-02-27
CA2457799C (en) 2014-05-27
AU2007201809A1 (en) 2007-05-17
US20080182276A1 (en) 2008-07-31
AU2010241288B2 (en) 2012-05-31
EP1427810A2 (de) 2004-06-16
JP2005527781A (ja) 2005-09-15
AU2007201809B2 (en) 2010-08-05
EP1427810B9 (de) 2012-04-25

Similar Documents

Publication Publication Date Title
ATE530635T1 (de) Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status
WO2008060651A3 (en) Sparc and methods of use thereof
DE60238493D1 (de) Is von seltenen zellen verwendete markierte zellen
DK1198585T3 (da) Fremgangsmåde til karakterisering af en biologisk tilstand ved anvendelse af kalibrerede genudtrykkelsesprofiler
DE60012716D1 (de) Neue halbleiternanopartikel zur analyse von blutzellpopulationen
WO2002003075A3 (en) Methods for detecting activity of clotting factors
DK2216416T3 (da) Fremgangsmåder til detektering af nukleinsyresekvenser i urin
WO2003066876A3 (en) An apparatus and methods for using biological material to discriminate an agent
NO20074389L (no) Bestemmelse av respondere til kjemoterapi
EE05675B1 (et) Meetod konformse haiguse diagnoosimiseks v?i tuvastamiseks, selleks vajalik katsemenetlus, reaktiivikomplekt ning seade
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
WO2004057021A3 (en) Molecular methods and compositions for detecting and quantifying respiratory viruses
WO2005084109A3 (en) Cancer specific gene mh15
WO2007135568A3 (en) A METHOD FOR PREDICTING RESPONSIVENESS TO TNFα BLOCKING AGENTS
WO2006044748A3 (en) RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
WO2004062570A3 (en) Apparatus and method to measure platelet contractility
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
IL184873A0 (en) Method for determining responsiveness to chk1 inhibitors
WO2003087761A3 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
DE60306865D1 (de) Detektion von Vancomycin-resistenten Enterococcus-Subspezies
ATE434762T1 (de) Biologischer marker für entzündung
WO2002057793A3 (en) Method of detecting prp protein and kits therefor
DE60126991D1 (de) Verfahren ZUR DIAGNOSE VON SCHIZOPHRENIE
EP1670497A4 (de) Verfahren zur identifizierung von modulatoren von proteinkinase c epsilon (pkcϵ) und verfahren zur behandlung von damit zusammenhängendem abweichendem glucose-stoffwechsel
GB0625756D0 (en) Analyte delection system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties